Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma

Published:2024-03-18 Issue:1 Volume:9 Page:17-24
ISSN:2380-8993
Container-title:Expert Review of Precision Medicine and Drug Development
language:en
Short-container-title:Expert Review of Precision Medicine and Drug Development

Author:

Mollica Veronica¹²,Rosellini Matteo¹²,Brocchi Stefano³,Galuppi Francesco³,Paccapelo Alexandro³,Tateo Valentina⁴,Marchetti Andrea¹²,Tassinari Elisa¹²,Mantuano Francesco¹²,Santoni Matteo⁵,Massari Francesco¹²

Affiliation:

1. Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

2. Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy

3. Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

4. Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy

5. Oncology Unit, Macerata Hospital, Macerata, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/23808993.2024.2330422

Reference32 articles.

1. Cancer statistics, 2023

2. Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities

3. Treatment selection in first-line metastatic renal cell carcinoma—the contemporary treatment paradigm in the age of combination therapy: a review;Navani V;JAMA Oncol,2022

4. Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer

5. Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis